论文部分内容阅读
目的研究替比夫定治疗HBeAg阳性慢性乙型肝炎的近期疗效。方法对46例HBeAg阳性慢性乙型病毒性肝炎初治患者(观察组)口服替比夫定治疗48周,对照组46例采用恩替卡韦治疗,对比观察两组的疗效。结果治疗48周后两组HBV-DNA的阴转率和ALT复常率差异无统计学意义(P>0.05);HBeAg阴转及血清学转换差异具有统计学意义(P<0.05)。结论替比夫定可以快速有效地抑制HBV的复制,明显改善临床症状及肝功能,在HBeAg阴转及血清学转换方面优于恩替卡韦。
Objective To study the short-term effect of telbivudine in the treatment of HBeAg-positive chronic hepatitis B patients. Methods Forty-six patients with initial HBeAg-positive chronic hepatitis B (observation group) were treated with telbivudine for 48 weeks, and 46 patients in the control group were treated with entecavir. The curative effect was compared between the two groups. Results After 48 weeks of treatment, there was no significant difference in the negative conversion rate of HBV-DNA and ALT between the two groups (P> 0.05). The difference of HBeAg negative conversion and seroconversion was statistically significant (P <0.05). Conclusion Telbivudine can inhibit the replication of HBV rapidly and effectively, improve the clinical symptoms and liver function significantly, and is superior to entecavir in HBeAg negative conversion and seroconversion.